

ASX Announcement

Date of AGM and Closing Date for Director Nominations

22 September 2026

Ceretas Limited (ASX: CTS) (Company) advises that in accordance with ASX Listing Rule 3.13.1 that it will hold its Annual General Meeting (AGM) at 10.00am (AEST) on Friday, 20 November 2026 at the offices of BDO Brisbane, Level 18, 360 Queen Street, Brisbane QLD 4000.

Shareholders will be advised of further details regarding the AGM in a separate Notice of Meeting, which will be provided to shareholders during October. The Notice of Meeting will also be available on the ASX Company Announcements Platform and the Company's website at www.ceretas.com.au.

In accordance with article 7.5 of the Company's Constitution, the closing date for receipt of nominations from persons who wish to be considered for election as a director is Friday, 2 October 2026. Any nominations must be received in writing no later than 5.00pm (AEST) on 2 October 2026 at the Company's registered office.

This announcement is authorised for release by the Board of Directors.

- ENDS -

For further information please contact

Henry Jordan

Six Degrees Investor Relations

henry.jordan@sdir.com.au

+61 (0)431 271 538

Dr Rachel de las Heras

Chief Executive Officer & Managing Director

racheldelasheras@ceretas.com.au

+61 (0)437 338 079

About Ceretas

Ceretas (ASX:CTS) is a clinical-stage medical technology company developing a portable, non-invasive therapeutic ultrasound platform to treat Alzheimer's disease and other neurodegenerative conditions.

The Ceretas device directs low-intensity focused ultrasound through the skull to act on brain tissue via two mechanisms: neuromodulation, targeting neural circuits involved in memory, cognition and the behavioural and psychological symptoms of dementia; and blood-brain barrier opening, which may facilitate clearance of disease-associated proteins and enhance delivery of therapeutic agents to the brain.

The technology is based on more than a decade of research at The University of Queensland and the Queensland Brain Institute (QBI). In 2024, QBI researchers completed a first-in-human Phase 1 trial of low-intensity focused ultrasound neuromodulation in 12 Alzheimer's participants, finding the treatment to be fast, safe and well tolerated, with encouraging early signals of benefit for behavioural symptoms. The results were published in Brain Communications in December 2025.

Ceretas is preparing to commence its Phase 2 CERE-CALM trial (ACTRN12626000738325), evaluating the platform in Alzheimer's patients with behavioural and psychological symptoms of dementia. QBI researchers are separately running their Phase 2 AGIFUS trial (ACTRN12626000687392), evaluating the same technology in Alzheimer's-related agitation, funded independently by Queensland Health.